-
About Us
About Us
The word “Amicogen” consists of the meaning of friend, “AMICO”
in Latin and of gene, “GENE”. We developed innovative biocatalysts
and proteins by applying our proprietary i DNA Evolution™ Technology.
We are a “Bioengineering company just like a Sincere Friend”
who contributes to the human health and the preservation of environment.
Amicogen is the representative Industrial Biotechnology Company in Korea
and wants to contribute to the protection of human health and the environment. -
R&D
R&D
Amicogen Biotech R&D Center is expanding its R&D field based on
bio-platform technology, and researchers account for 30% of all employees.
We will lead the Industrial Biotechnology to develop new technologies
that can drive the development of humanity and society,
one step further than others.
Amicogen continues innovative research
and development for its first and best products. -
Products
Products
Amicogen has developed Special Enzymes for industrial and pharmaceutical products based on the i DNA evolution™.
We want to contribute to the sustainable growth and lifelong health
of humanity by developing New Bio-Ingredientfor Health functional foods
with Special Enzymes and Protein Purification Resin.
Amicogen develops Bio Products and
New Bio-Ingredients for Health functional food. -
Investors
Investors
As Amicogen started as a bio-venture company, we have focused on
the core competence of R&D and are pursuing sustainable growth
in innovative technologies and products. To increase the value
of enterprise and shareholder, we are continually strengthening our core competencies such as specialty enzyme business, healthcare, protein
purification resin business and others.
Amicogen strengthens key capacities
to increase enterprise value and shareholder value. -
Media
Media
Amicogen promotes various activities to realize the value of contributing
to the protection of human health and the environment.
Amicogen is positioning itself as a global biotechnology company
through growth and leaps to create new values.
You can find various looks and news of Amicogen
taking the initiative in the global bio industry. -
ESG
Sustainable management
Amicogen has developed bio innovative technologies and operated the businesses that consider humankind and environment from the perspective of sustainability for the past 20 years. We will continue sustainable development based on Amicogen's environmental soundness, social responsibility and sustainable innovative technology.
Amicogen wants to contribute to the protection of human health and the environment. -
Careers
Careers
Amicogen produces new technologies and values based on
creative thinking and constant technological innovation through human
oriented management. We do our best to ensure that talented individuals
with unique skills and abilities can demonstrate their abilities
according to the nature of their duties.
We are waiting for Amicogen people,
who will open new values and a bright future. -
CONTACT
Careers
Amicogen produces new technologies and values based on
creative thinking and constant technological innovation through human
oriented management. We do our best to ensure that talented individuals
with unique skills and abilities can demonstrate their abilities
according to the nature of their duties.We are waiting for Amicogen people,
who will open new values and a bright future.
Amicogen
Our Story & History
Amicogen is a global leading industrial biotechnology company.
Amicogen creates sustainability of health industry and our planet.
Amicogen creates new values that can sustain growth.
'The world's first 7-ACA first-stage enzyme (CX enzyme)', 'The world's first complete enzymatic decomposition method N-Acetylglucosamine'
By developing innovative products that other companies do not try, we are creating new value by enhancing differentiation.
Period of growth 2011~Present
2022
- 12
- Received the Minister of Trade, Industry and Energy Award on the Bio Entrepreneurs' Day of 2022 (Regional Development Category) - Munsan 3 Factory
- 05
- Purchased land in Yeosu National Industrial Complex, Jeonnam, South Korea by Puriogen (to establish a resin factory for biopharmaceutical production)
- 04
- Strategic investment in InThera, Co., Ltd., a vaccine development company based on VLP platform technology
- Completed approval of Amicogen China’s finished drug of tulathromycin in China
- 02
- Started construction of a medium factory for biopharmaceutical production in Songdo
- 01
- Completed the new factory for healthcare (ODM/OEM) in Jinju (approx. 9,500㎡)
2021
- 09
- Lysando AG quota investment
- Bifido Co., Ltd. quota investment
- 08
- Autobulin Therapeutics, Inc. quota investment
- 07
- MediPL, Co., Ltd. quota investment
- Established ‘AMINAVICO’ joint venture in Vietnam
- 06
- Puriogen, Inc. quota investment
- 05
- Purchased Munsan 4 factory site
- 02
- Concluded resin production technology transfer agreement with Bioworks AG.
- 01
- Concluded Collagen-Peptide supply agreement with Amorepacific Aestura
- Applied Keto acid Covid-19 Antivirus patent application.
2020
- 12
- Endolysin technology introduction contract conclusion with Lysando
- Excellent enterprise award in the bio industry (Ministry of Trade, Industry and Energy)
- 11
- Selected as the best IR enterprise by Money Today for leading edge biomaterial division
- 09
- Selected as a national project for biopharmaceutical resin localization
- JV contract conclusion with Artiabio for the introduction of medium technology
- 05
- Munsan 3 Factory Vgurt factory extension
- 04
- Selected as a national project for biopharmaceutical medium localization
- 03
- Established ‘AMINAVICO’ a Vietnam joint venture (catfish skin gelatinization business)
2019
- 12
- Local and China Collagen peptide manufacturing facility establishment completed (700t/year)
- Excellent corp. laboratory appointment
- Completion of collagen peptide plants in Soth Korea and China (700 tons per year)
- 11
- Technology Grand Prize Participation prize by Korea Food Research Institute
- 05
- liver health functional claim approved by KFDA(PINITOL)
- 04
- Munsan 1st manufacturing site with capacity expansion(5t/month) Protein purification laboratory ISO 9001 acquisition
- Global Small Hidden Champion(Ministry of SMEs and Startups(MSS)
- 02
- Related Company, Cellid listed on the KOSDAQ stock exchange market in South Korea
2018
- 06
- Protein Purification & Resin Biz unit relocation to Seoul Office
- 05
- YBB Bio Inc. 100% quota investment
- 04
- 2018 Health Functional Food award by Ministry of Agriculture, Food and Rural Affairs(MAFRA) – ‘K nutra’s Joint Bone’ Onion holdings 100% quota investment ‘Green cefazolin synthesis technology development’ Industrial Innovation biz appointment
- 03
- Kangmaicheon JV contract completed(China CP manufacturing site establishment and biz development)
2017
- 12
- Bio-Works Technologies listed in Firstnorth Nasdaq stock market
- 05
- Bio-Works Technologies AB quota investment
- 04
- Biocogen, Inc. quota additional investment
- 01
- Amicogen Pacific, Inc. quota additional investment
2016
- 12
- Shaghai hanwook limited minister quota disposal completed
- 10
- Korea Best Brand award appointment(healthcare) by Korea Economic Magazine
- 09
- Purchase of Munsan 2nd manufacturing site building and land
- 07
- Company name change-Longevity Korea, Inc. to Amicogen Pacific, Inc.
- 06
- Clinomics, Inc. convertible bond take over PearlZyme, Inc. convertible bond take over
2015
- 12
- PearlZyme, Inc. convertible bond take over Jeilgreen Industry, Inc. convertible bond take over
- 11
- Clinomics, Inc. quota investment
- 10
- Shanghai hanwook cosmetics limited minister quota investment
- 09
- Shandong lukang liker medcine limited minister quota investment
- 08
- Longevity Korea(currently Amicogen Pacific) quota investment
- 07
- SKINMED, Inc. quota investment
- 04
- Global Leader Corp. appointment by Everyday economic
- 03
- Good example of taxpayer award by the Commissioner of Customs award certificate
2014
- 10
- Biocogen, Inc. quota investment
- 07
- Biotech R&D center establishment
- 06
- Cellid, Inc. quota investment
- 04
- Keumho hwasung quota take over(currently Amicogen C&C, Inc.) Finland Labmaster, Oy quota investment
- 03
- Shandong Amicogen Biotechnology limited minister quota investment
2013
- 12
- Export 10 million dollars achievement
- 09
- Korea Exchange KOSDAQ listed
- 07
- Gyeongsangnam-do excellent employment corporation certification
- 05
- Seoul Office establishment
2012
- 12
- Export 5 million dollars award, The celebration day of export presidential award
- 10
- Manufacturing facility construction complete for food grade-enzyme
2011
- 12
- World-class goods appointment(N-Acetyl Glucosamine)
- 10
- Special Enzyme(CX) for medicine – export start
- 09
- Enzyme manufacturing facility set-up(Munsan)
- 08
- Exclusive contract sign with China Lukang corp.